Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1900B||SWOG||A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0931||SWOG||EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy; A Phase III Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0221||SWOG||Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0502||SWOG||A Phase III Randomized Study of Imatinib; with or without Bevacizumab (NSC-704865); in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT #00324987||Adult CIRB - Late Phase Emphasis||Completed|
|S1404||SWOG||A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1612||SWOG||A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1703||SWOG||Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer||Cancer Prevention and Control CIRB||Available to Open|
|S1900C||SWOG||A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1905||SWOG||A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1801||SWOG||A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Sage III-IV High Risk Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|